DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting

World News: . []

Montrouge, France, November 9, 2018

DBV Technologies to Present Data Further Supporting the Use of Epicutaneous Immunotherapy for the Treatment of Peanut Allergy at the 2018 ACAAI Meeting

Three abstracts on Viaskin Peanut accepted for oral presentation

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that additional analyses from clinical trials of Viaskin Peanut will be presented at the 2018 American College of Allergy, Asthma, and Immunology (ACAAI) in Seattle, Washington, November 15-19, 2018.

Oral Presentations:

"Increased Reactivity Threshold in Peanut-allergic Subjects Treated With 12 Months of Epicutaneous Viaskin Peanut" will be presented by Dr. Carla M. Davis, Texas Children's Hospital and Baylor College of Medicine, Houston, TX.

  • Oral Abstracts Session 2B: Food Allergy
  • A303
  • Sunday, November 18 / 3:45 - 4:00 PM PT

 "Quantitative Risk Reduction Through Epicutaneous Immunotherapy (EPIT): Results from the PEPITES Phase III Trial" will be presented by Dr. Benjamin C. Remington, TNO Ziest, The Netherlands.

  • Oral Abstracts Session 2B: Food Allergy
  • A302
  • Sunday, November 18 / 3:30 - 3:45 PM PT

"Serum Biomarkers of Immunomodulation During Peanut Epicutaneous Immunotherapy (EPIT) in Peanut-allergic Subjects" will be presented by Dr. Matthew Greenhawt, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO.

  • Oral Abstracts Session 4A: Clinical Immunology, Immunodeficiency
  • A305
  • Monday, November 19 / 11:15 - 11:30 AM PT

About DBV Technologies 

DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. The Company's ordinary shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740

DBV Media Contact
Joe Becker
VP, Global Corporate Communications

PDF Version

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire

More news and information about DBV Technologies

Published By:

Thomson Reuters: 06:31 GMT Friday 9th November 2018

Published: .

Search for other references to "technologies" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us